Diabetic nephropathy is a major cause of diabetes-related morbidity and mortality; however the clinical course of the disease and the renal prognosis is highly variable among individuals. The current review will discuss the genetic influence on the development of end stage renal disease (ESRD) in diabetic patients and potential improvements to the current treatment strategy to slow the loss of kidney function in these patients. In this first part, the growing evidence that glucose-induced activation of the intra-renal and systemic renin-angiotensin systems plays an essential role in processes leading to destruction of renal function is summarised. Genetic variations, especially the angiotensin-converting enzyme (ACE)/ID polymorphisms in the gene coding for ACE, are involved in activation of the renin-angiotensin system and seem to influence the clinical course of diabetic nephropathy during treatment with ACE inhibitors. In addition, this polymorphism may interact with other polymorphisms within the reninangiotensin system, leading to high risk of ESRD. As new genetic approaches and methods develop, further understanding of diabetic nephropathy will evolve and genotyping will help prevent ESRD in diabetic patients.
Powers ACDiabetes Mellitus. In: Braunwald E , Fauci AS, Isselbacher KJ et al., editors. Harrison Online. Isselbacher KJ et al., editors. Harrison Online. New York: The McGraw-Hill Companies, 2002.
2.
Parving H-H., sterby R., Ritz E.Diabetic nephropathy. In: Brenner BM, editor. The Kidney. Philadelphia: WB Saunders, 2000: 1731-73.
3.
Parving H-H. , Viberti GC, Keen H., Christiansen JS, Lassen NAHemodynamic factors in the genesis of diabetic microangiopathy. Metabolism1983;32:943-9.
4.
Porte D., Jr., Schwartz MWDiabetes complications: why is glucose potentially toxic?Science1996;272:699-700.
5.
Cooper MEPathogenesis, prevention, and treatment of diabetic nephropathy. Lancet1998;352:213-19.
6.
Cooper MEInteraction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia2001;44:1957-72.
7.
Brenner BM, Meyer TW, Hostetter THDietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease . N Engl J Med1982;307:652-9.
8.
Hostetter TH , Rennke HG, Brenner BMThe case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies . Am J Med1982;72:375-80.
9.
Remuzzi G., Bertani T.Pathophysiology of progressive nephropathies. N Engl J Med1998;339:1448-56.
10.
Fogo ABProgression and potential regression of glomerulosclerosis. Kidney Int2001;59:804-19.
11.
Rossing P.Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. Diabet Med1998 ;15:900-19.
Jacobsen P. , Tarnow L., Carstensen B., Hovind P., Poirier O., Parving H-H .Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy . J Am Soc Nephrol2003;14:2843-50.
14.
Bjorck S., Mulec H., Johnsen SA, Norden G., Aurell M.Renal protective effect of enalapril in diabetic nephropathy. Br Med J1992;304:339-43.
15.
Kasiske BL, Kalil RS, Ma JZ, Liao M., Keane WFEffect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med1993;118:129-38.
16.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med1993;329:1456-62.
17.
Bilous RWBaseline and change in proteinuria and the risk of renal functional loss in the Irbesartan Diabetic Nephropathy Trial (IDNT). Diabet Med2003;20(suppl 2):1-33.
18.
Ruggenenti P., Perna A., Remuzzi G.Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int2003;63:2254-61.
19.
De Zeeuw D. , Remuzzi G., Parving H-H et al. Proteinuria reduction during antihypertensive therapy predicts renal and cardio-vascular protection in patients with Type 2 diabetic nephropathy. Diabetologia2003;46(supplement 2):A339.
20.
De Jong PE, Navis G., De Zeeuw D.Renoprotective therapy: titration against urinary protein excretion. Lancet1999;354:352-3.
21.
Mogensen CELong-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Ed)1982;285:685-8.
22.
Parving H-H. , Andersen AR, Smidt UM, Svendsen PAEarly aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet1983;1: 1175-9.
23.
Parving H-H. , Jacobsen P., Rossing K., Smidt UM, Hommel E., Rossing P.Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int1996;49:1778-82.
24.
Rossing P., Hougaard P., Borch-Johnsen K., Parving H-H.Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. Br Med J1996;313:779-84.
25.
Raij L., Chiou XC, Owens R., Wrigley B.Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model. Am J Med1985;79:37-41.
26.
Anderson S. , Rennke HG, Brenner BMTherapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest1986 ;77:1993-2000.
27.
Anderson S. , Rennke HG, Garcia DL, Brenner BMShort and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int1989 ;36:526-36.
28.
Taguma Y., Kitamoto Y., Futaki G.et al. Effect of captopril on heavy proteinuria in azotemic diabetics . N Engl J Med1985; 313:1617-20.
29.
Parving H-H. , Hommel E., Smidt UMProtection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy . Br Med J1988; 297:1086-91.
30.
Brenner BM, Cooper ME, De Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001;345:861-9.
31.
Viberti G., Mogensen CE, Groop LC, Pauls JFEffect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA1994;271:275-9.
32.
Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001;345:851-60.
33.
Parving H-H. , Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes . N Engl J Med2001;345:870-8.
34.
Giatras I., Lau J., Levey ASEffect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med1997;127:337-45.
35.
Jafar TH, Schmid CH, Landa M. et al.Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med2001;135:73-87.
36.
Zatz R., Dunn BR, Meyer TW, Anderson S., Rennke HG, Brenner BMPrevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest1986 ;77:1925-30.
37.
Fogo A., Yoshida Y., Glick AD, Homma T., Ichikawa I.Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest1988 ;82:322-30.
38.
Bohrer MP, Deen WM, Robertson CR, Brenner BMMechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol1977;233:F13-F21.
39.
Lapinski R. , Perico N., Remuzzi A., Sangalli F., Benigni A., Remuzzi G.Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney . J Am Soc Nephrol1996;7:653-60.
40.
Leehey DJ, SinghAK,Alavi N., Singh R.Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl2000;77:S93-S98. 41. Rincon-Choles H., Kasinath BS, Gorin Y., Abboud HEAngiotensin II and growth factors in the pathogenesis of diabetic nephropathy . Kidney Int Suppl2002;82:8-11.
41.
Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JSMolecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int1999;55:454-64.
42.
Wolf G.Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant2000;15(suppl 6):61-3.
43.
Burns KDAngiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis2000;36:449-67.
44.
Taal MW, Brenner BMRenoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists . Kidney Int2000;57:1803-17.
45.
Zatz R., Brenner BMPathogenesis of diabetic microangiopathy.The hemodynamic view. Am J Med1986;80:443-53.
46.
Osei SY, Price DA, Fisher ND, Porter L., Laffel LM, Hollenberg NKHyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. Hypertension1999;33(1 Pt 2):559-64.
47.
Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NKEffect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension2000;36:122-6.
48.
Miller JA, Floras JS, Zinman B., Skorecki KL, LoganAGEffect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci (Lond)1996;90: 189-95.
49.
Miller JAImpact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol1999 ;10:1778-85.
50.
Price DA, Porter LE, Gordon M. et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol1999;10:2382-91.
51.
Imanishi M. , Yoshioka K., Konishi Y. et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia1999;42:999-1005.
52.
Mizuiri S., Yoshikawa H., Tanegashima M. et al. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis1998;31:301-07.
53.
Christlieb AR, Kaldany A., D'Elia JAPlasma renin activity and hypertension in diabetes mellitus. Diabetes1976;25:96974.
54.
Perez GO, Lespier L., Jacobi J. et al. Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med1977;137:852-5.
55.
Wolf G., Ziyadeh FNThe role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms.Am J Kidney Dis1997;29:153-63.
56.
Hommel E., Mathiesen ER, Giese J., Nielsen MD, Schutten HJ, Parving H-H.On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy. Scand J Clin Lab Invest1989;49:537-44.
57.
Deinum J.,Tarnow L., van Gool JM et al. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant1999;14:1904-11.
58.
O'Hara JA, Ferriss JB,Twomey BM, Gonggrijp H., O'Sullivan DJChanges in blood pressure, body fluids, circulating angiotensin II and aldosterone, with improved diabetic control. Clinical Science1982;63:415s-418s.
59.
Lieberman J. , Sastre A.Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann Intern Med1980; 93:825-6.
60.
Marre M., Bernadet P., Gallois Y. et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes1994;43:384-8.
61.
Tarnow L., Cambien F., Rossing P. et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes1995 ;44:489-94.
62.
Florey CV, Uppal S., Lowy C.Relation between blood pressure, weight, and plasma sugar and serum insulin levels in schoolchildren aged 9-12 years in Westland, Holland. Br Med J1976;1:1368-71.
63.
Jarrett RJ, Keen H., McCartney M. et al. Glucose tolerance and blood pressure in two population samples: their relation to diabetes mellitus and hypertension.IntJEpidemiol1978;7:15-24.
64.
Mathiesen ER , Hilsted J., Feldt-Rasmussen B., Bonde-Petersen F., Christensen NJ, Parving H-H.The effect of metabolic control on hemodynamics in short-term insulin-dependent diabetic patients. Diabetes1985;34:1301-05.
65.
Parving H-H. , Noer I., Deckert T. et al. The effect of metabolic regulation on microvascular permeability to small and large molecules in short-term juvenile diabetics. Diabetologia1976;12:161-6.
66.
Marfella R. , Nappo F., De Angelis L., Paolisso G., Tagliamonte MR, Giugliano D.Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients. Diabetes Care2000;23:658-63. 68. Jacobsen P., Rossing K., Hansen BV, Bie P., Vaag A., Parving H-H.Effect of short-term hyperglycaemia on haemodynamics in type 1 diabetic patients . J Intern Med2003;254:464-71.
67.
Kastrup J., Rorsgaard S., Parving H-H., Lassen NAImpaired autoregulation of cerebral blood flow in long-term type I (insulin-dependent) diabetic patients with nephropathy and retinopathy. Clin Physiol1986;6:549-59.
68.
Kastrup J., Norgaard T., Parving H-H., Henriksen O., Lassen NAImpaired autoregulation of blood flow in subcutaneous tissue of long-term type 1 (insulin-dependent) diabetic patients with microangiopathy: an index of arteriolar dysfunction. Diabetologia1985 ;28:711-17.
69.
Parving H-H. , Kastrup H., Smidt UM, Andersen AR, Feldt-Rasmussen B., Christiansen JSImpaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia1984;27:547-52.
70.
Christensen PK, Hansen HP, Parving H-H .Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int1997;52:1369-74.
71.
Seaquist ER , Goetz FC, Rich S., Barbosa J.Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med1989;320:1161-5.
72.
Schelling JR , Zarif L., Sehgal A., Iyengar S., Sedor JRGenetic susceptibility to end-stage renal disease. Curr Opin Nephrol Hypertens1999;8:465-72.
73.
Tarnow L.Diabetic nephropathy. Pathogenetic aspects and cardiovascular risk factors . Dan Med Bull2002;49:19-42.
74.
Krolewski ASGenetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int1999 ;55:1582-96.
75.
Wang PH, Lau J., Chalmers TCMeta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes.Lancet1993 ;341:1306-09.
76.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med1993;329: 977-86.
77.
Lander ES, Linton LM, Birren B. et al. Initial sequencing and analysis of the human genome. Nature2001;409:860-921.
78.
Venter JC,Adams MD, Myers EW et al.The sequence of the human genome. Science2001;291:1304-51.
79.
Gambaro G., Anglani F., D'Angelo A.Association studies of genetic polymorphisms and complex disease. Lancet2000; 355:308-11.
80.
Freely associating. Nat Genet1999;22:1-2.
81.
Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E.Antihypertensive pharmacogenetics: getting the right drug into the right patient . J Hypertens2001;19:1-11.
82.
Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F.An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest1990;86:1343-6.
83.
HunleyTE ,Julian BA, Phillips JA, III et al.Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy . Kidney Int1996;49:571-7.
84.
Mizuiri S., Hemmi H., Kumanomidou H. et al. Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. Kidney Int2001;60:1124-30.
85.
Staessen JA , Wang JG, Ginocchio G. et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens1997;15:1579-92.
86.
Fujisawa T. , Ikegami H., Kawaguchi Y. et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia1998;41:47-53.
87.
Tarnow L., Gluud C., Parving H-H.Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant1998;13: 1125-30.
88.
Rudberg S., Rasmussen LM, Bangstad HJ, Osterby R.Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria . Diabetes Care2000; 23:544-8.
89.
SoliniA,DallaVM,SallerA.,Nosadini R., Crepaldi G., Fioretto P.The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes2002;51:251-5.
90.
Harden PN, Geddes C., Rowe PA et al. Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet1995;345:1540-2.
91.
Yoshida H., Mitarai T., KawamuraT. et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy . J Clin Invest1995;96:2162-9.
92.
Parving H-H. , Jacobsen P., Tarnow L. et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Br Med J1996;313:591-4.
93.
Jacobsen P. , Rossing K., Rossing P. et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int1998;53:1002-06.
94.
Penno G., Chaturvedi N., Talmud PJ et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes1998 ;47:1507-11.
95.
Parving H-H. , Hommel E., Mathiesen E. et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed)1988;296:156-60.
96.
Jacobsen P. , Rossing K.,Tarnow L. et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl1999;71:S101-S105.
97.
Bjorck S., Blohme G., Sylven C., Mulec H.Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant1997;12(suppl 2):67-70.
98.
Hadjadj S. , Belloum R., Bouhanick B. et al. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol2001;12:541-9.
99.
Gumprecht J., Zychma MJ, Grzeszczak W., ZukowskaSzczechowska E.Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group. Kidney Int2000;58:513-19.
100.
Fava S., Azzopardi J., Ellard S., Hattersley ATACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. Diabetes Care2001;24: 2115-20.
101.
Tomino Y., Makita Y., Shike T. et al. Relationship between polymorphism in the angiotensinogen, angiotensin- converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron1999;82:139-44.
102.
Yoshida H. , Kuriyama S.,Atsumi Y. et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus . Kidney Int1996;50:657-64.
103.
Marre M., Jeunemaitre X., Gallois Y. et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest1997;99:1585-95.
104.
Schmidt S. , Strojek K., Grzeszczak W., Bergis K., Ritz E.Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant1997 ;12:427-9.
105.
Kimura H., Gejyo F., Suzuki Y., Suzuki S., Miyazaki R.,Arakawa M.Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy-1. Kidney Int1998;54:1659-69.
106.
Vleming LJ , van der Pijl JW et al.The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol1999;51:133-40.
107.
Wong TY, Chan JC, Poon E., Li PKLack of association of angiotensin-converting enzyme (DD/II) and angiotensinogen M235T gene polymorphism with renal function among Chinese patients with type II diabetes. Am J Kidney Dis1999; 33:1064-70.
108.
Lovati E., Richard A., Frey BM, Frey FJ, Ferrari P.Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int2001 ;60:46-54.
109.
Ha SK, Park HC, Park HS et al. ACE gene polymorphism and progression of diabetic nephropathy in Korean type 2 diabetic patients: Effect of ACE gene DD on the progression of diabetic nephropathy. Am J Kidney Dis2003 ;41:943-9.
110.
Taal MWAngiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant?Curr Opin Nephrol Hypertens2000 ;9:651-7.
111.
Schena FP, D'Altri C., Cerullo G., Manno C., Gesualdo L.ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. Kidney Int2001;60:732-40. 114. Greene T., Lau J., Levey ASImmunological Renal Diseases. CouserWG, 1997.
112.
Levey AS, Greene T., Beck GJ et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol1999;10:2426-39.
113.
Ruggenenti P., Perna A., Gherardi G. et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354:359-64. 117. van der Kleij FG , Schmidt A., Navis GJ et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int Suppl1998;53(suppl 63):S23-S26.
114.
van der Kleij FG, De Jong PE, Henning RH, De Zeeuw D., Navis G.Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol2002 ;13: 1025-33.
115.
Jackson B. , Johnston CIAngiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension. Clin Exp Pharmacol Physiol1984;11:355-9.
116.
Andersen S. , Tarnow L., Cambien F. et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?Kidney Int2002;62:192-8.
117.
Andersen S. , Tarnow L., Cambien F. et al. Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE insertion/deletion genotype?Diabetes Care2003;26:1501-06.
118.
Keavney B. , McKenzie CA, Connell JM et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum Mol Genet1998;7:1745-51.
119.
Walker WG, Whelton PK, Saito H., Russell RP, Hermann J.Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects . Hypertension1979;1:287-91.
120.
Jeunemaitre X., Soubrier F., Kotelevtsev YV et al. Molecular basis of human hypertension: role of angiotensinogen. Cell1992;71:169-80.
121.
Inoue I., NakajimaT,Williams CS et al.A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest1997;99:1786-97.
122.
Hopkins PN , Lifton RP, Hollenberg NK et al. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens1996;14:199-207.
123.
Paillard F. , Chansel D., Brand E. et al. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population . Hypertension1999;34:423-9.
124.
Rotimi C., Morrison L., Cooper R. et al. Angiotensinogen gene in human hypertension. Lack of an association of the 235T allele among African Americans. Hypertension1994;24: 591-4.
125.
Hingorani AD, Jia H., Stevens PA, Hopper R., Dickerson JE, Brown MJRenin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens1995;13:1602-09.
126.
de Gasparo M., Catt KJ, Inagami T., Wright JW, Unger T.International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev2000;52:415-72.
127.
BonnardeauxA,Davies E.,Jeunemaitre X. et al.Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension.Hypertension1994;24:63-9.
128.
Miller JA, Thai K., Scholey JWAngiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int1999;56:2173-80.
129.
Miller JA, Thai K., Scholey JWAngiotensin II type 1 receptor gene polymorphism and the response to hyperglycemia in early type 1 diabetes. Diabetes2000:49:1585-9.
130.
Duncan JA, Scholey JW, Miller JAAngiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes. Curr Opin Nephrol Hypertens2001;10:111-16.
131.
Frimat L., Philippe C., Maghakian MN et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274 Men. J Am Soc Nephrol2000;11:2062-7.
Cadman PE, O'Connor DTPharmacogenomics of hypertension. Curr Opin Nephrol Hypertens2003;12:61-70.
134.
Evans WE, McLeod HLPharmacogenomics--drug disposition, drug targets, and side effects . N Engl JMed2003;348:538-49.
135.
Savage DB,Agostini M., Barroso I. et al. Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet2002;31:379-84.
136.
Pei Y., Scholey J.,Thai K., Suzuki M., Cattran D.Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest1997;100:814-20.
137.
Bantis C., Ivens K., Kreusser W. et al. Influence of Genetic Polymorphisms in the Renin Angiotensin System on IgA Nephropathy. J Am Soc Nephrol2001;12[(abstract)]:91A.
138.
Kurland L. , Melhus H., Karlsson J. et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial .JHypertens2002;20:657-63.
139.
Yip J. , Mattock MB, Morocutti A., Sethi M., Trevisan R., Viberti G.Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet1993 ;342:883-7.
140.
De Cosmo S. , Bacci S., Piras GP et al. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia1997;40:1191-6.
141.
Reaven GMBanting lecture 1988. Role of insulin resistance in human disease . Diabetes1988;37:1595-607.
142.
Maddux BA, Sbraccia P., Kumakura S. et al. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus.Nature1995;373:448-51.
143.
Frittitta L., Youngren J., Vigneri R., Maddux BA, Trischitta V., Goldfine IDPC-1 content in skeletal muscle of non-obese, nondiabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia1996;39:1190-5.
144.
Frittitta L.,Youngren JF, Sbraccia P. et al. Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia1997 ;40:282-9.
145.
Frittitta L., Spampinato D., Solini A. et al. Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes1998;47:1095-100.
146.
Maddux BA, Goldfine IDMembrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes2000;49:13-19.
147.
Pizzuti A. , Frittitta L., Argiolas A. et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance . Diabetes1999; 48:1881-4.
148.
Gu HF, Almgren P., Lindholm E. et al. Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis. Diabetes2000;49: 1601-03.
149.
Costanzo BV , Trischitta V., Di Paola R. et al. The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (LYS121). Diabetes2001;50:831-6.
150.
Rasmussen SK, Urhammer SA, Pizzuti A. et al. The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. Diabetes2000;49:1608-11.
151.
De Cosmo S. ,Argiolas A., Miscio G. et al.A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria. Diabetes2000;49:521-4.
152.
De Cosmo S. , Miscio G., Zucaro L. et al.The role of PC-1 and ACE genes in diabetic nephropathy in type 1 diabetic patients: evidence for a polygenic control of kidney disease progression. Nephrol Dial Transplant2002;17:1402-07.
153.
Jacobsen P. , Grarup N.,Tarnow L., Parving H-H., Pedersen O.PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients. Nephrol Dial Transplant2002;17:1408-12.
154.
Canani LH, Ng DP, Smiles A., Rogus JJ, Warram JH, Krolewski ASPolymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes . Diabetes2002;51:1188-93.
155.
Klahr S.The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant2001;16(suppl 1):60-2.
156.
Huang PL, Huang Z., Mashimo H. et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature1995;377:239-42.
157.
Wattanapitayakul SK, Mihm MJ, Young AP, Bauer JATherapeutic implications of human endothelial nitric oxide synthase gene polymorphism. Trends Pharmacol Sci2001;22: 361-8.
158.
Imperatore G., Hanson RL, Pettitt DJ, Kobes S., Bennett PH, Knowler WCSib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes1998;47:821-30.
159.
Zanchi A., Moczulski DK, Hanna LS, Wantman M., Warram JH, Krolewski ASRisk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int2000;57:405-13.
160.
Noiri E., Satoh H., Taguchi J. et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension2002;40:535-40.
Yamaguchi Y. , Mann DM, Ruoslahti E.Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature1990;346:281-4.
163.
Sakharova OV, Taal MW, Brenner BMPathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens2001;10:727-38.
164.
De Cosmo S. ,Tassi V.,Thomas S. et al.The Decorin gene 179 allelic variant is associated with a slower progression of renal disease in patients with type 1 diabetes. Nephron2002;92:72-6.
165.
Barlassina C., Schork NJ, Manunta P. et al. Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion . Kidney Int2000; 57:1083-90.
166.
Nicod J., Frey BM, Frey FJ, Ferrari P.Role of the alpha-adducin genotype on renal disease progression. Kidney Int2002;61:1270-5.
167.
Wang JG, Staessen JA,Tizzoni L. et al. Renal function in relation to three candidate genes. Am J Kidney Dis2001;38:1158-68.
168.
Narita I., Saito N., Goto S. et al. Role of uteroglobin G38A polymorphism in the progression of IgA nephropathy in Japanese patients. Kidney Int2002;61:1853-8.
169.
Neugarten J.,AcharyaA,Silbiger SREffect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol2000;11:319-29.
170.
Seliger SL , Davis C., Stehman-Breen C.Gender and the progression of renal disease . Curr Opin Nephrol Hypertens2001; 10:219-25.
171.
Neugarten J.Gender and the progression of renal disease . J Am Soc Nephrol2002;13:2807-09.
172.
Hodgkinson AD, Sondergaard KL, Yang B., Cross DF, Millward BA, Demaine AGAldose reductase expression is induced by hyperglycemia in diabetic nephropathy. Kidney Int2001;60:211-18.
173.
Nakajima H. , Takenaka M., Kaimori JY et al. Gene expression profile of renal proximal tubules regulated by proteinuria. Kidney Int2002;61:1577-87.
174.
van de Vijver MJ, He YD et al.A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med2002; 347:1999-2009.
